Tubulins - the target for anticancer therapy
- PMID: 25579568
- DOI: 10.2174/1568026615666150112115805
Tubulins - the target for anticancer therapy
Abstract
Tubulin has picked up great focus as a major target in drug discovery and consequently, tubulin inhibitors have pulling in a considerable attention as anticancer agents. Numerable naturally occurring agents have focused on tubulin system act as an imperative target of cancer chemotherapy. Substantial number of tubulin inhibitors has been discovered so far and these agents are classified as indicated by their interaction. They are colchicine site binder, vinca- alkaloid related drugs and those interacting with the Taxol binding site and functioning as stabilising agents. We review the recent advances in the advancement of tubulin interfering agents and will render the current trend in the improvement of tubulin inhibitors as anticancer agents.
Similar articles
-
Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.Curr Pharm Des. 1998 Jun;4(3):219-48. Curr Pharm Des. 1998. PMID: 10197041 Review.
-
Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.Eur J Med Chem. 2018 May 10;151:482-494. doi: 10.1016/j.ejmech.2018.04.011. Epub 2018 Apr 5. Eur J Med Chem. 2018. PMID: 29649743 Review.
-
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.Med Res Rev. 1998 Jul;18(4):259-96. doi: 10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u. Med Res Rev. 1998. PMID: 9664292 Review.
-
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13817-21. doi: 10.1073/pnas.1408124111. Epub 2014 Aug 11. Proc Natl Acad Sci U S A. 2014. PMID: 25114240 Free PMC article.
-
Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.Curr Top Med Chem. 2019;19(15):1289-1304. doi: 10.2174/1568026619666190618130008. Curr Top Med Chem. 2019. PMID: 31210108 Review.
Cited by
-
Design, Synthesis, Molecular Docking, and Biological Evaluation of Pyrazole Hybrid Chalcone Conjugates as Potential Anticancer Agents and Tubulin Polymerization Inhibitors.Pharmaceuticals (Basel). 2022 Feb 24;15(3):280. doi: 10.3390/ph15030280. Pharmaceuticals (Basel). 2022. PMID: 35337078 Free PMC article.
-
In Silico Conformation of the Drug Colchicine into Tubulin Models and Acute Phytotoxic Activity on Cucumis sativus Radicles.Plants (Basel). 2022 Jul 8;11(14):1805. doi: 10.3390/plants11141805. Plants (Basel). 2022. PMID: 35890440 Free PMC article.
-
CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance.Sci Rep. 2019 Dec 18;9(1):19384. doi: 10.1038/s41598-019-55526-8. Sci Rep. 2019. PMID: 31852908 Free PMC article.
-
Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine.Support Care Cancer. 2019 Oct;27(10):3869-3875. doi: 10.1007/s00520-019-4654-2. Epub 2019 Feb 14. Support Care Cancer. 2019. PMID: 30767130
-
Synthesis, Computational Analysis, and Antiproliferative Activity of Novel Benzimidazole Acrylonitriles as Tubulin Polymerization Inhibitors: Part 2.Pharmaceuticals (Basel). 2021 Oct 17;14(10):1052. doi: 10.3390/ph14101052. Pharmaceuticals (Basel). 2021. PMID: 34681276 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources